[Bupivacaine 0.5% CO2 in spinal anesthesia]

Area of Science:

• Anesthesiology
• Pharmacology

Context:

• Spinal anesthesia is a common procedure for surgical pain management.
• Bupivacaine hydrochloride (HCl) is a widely used local anesthetic for spinal anesthesia.
• The physical and chemical properties of anesthetic solutions can influence their clinical performance and safety.

Purpose:

• To evaluate the clinical efficacy and safety of 0.5% bupivacaine-CO2 for spinal anesthesia.
• To compare the onset, duration, and quality of spinal anesthesia induced by bupivacaine-CO2 versus bupivacaine-HCl.
• To assess the solubility characteristics of bupivacaine-CO2 in cerebrospinal fluid (CSF).

Summary:

• A study involving 45 patients demonstrated the safety of 0.5% bupivacaine-CO2 for spinal anesthesia, with no observed segmental deficits.
• Bupivacaine-CO2 exhibited a shorter latency period (7.7 minutes) compared to bupivacaine-HCl, while providing an identical duration of maximal analgesic spread (105 ± 31 minutes).
• A high incidence of complete motor blockade (93%) was achieved, and the increased solubility of bupivacaine-CO2 in CSF (1.75 mg/mL vs. 0.8 mg/mL for bupivacaine-HCl) potentially reduces precipitation risks.

Impact:

• 0.5% bupivacaine-CO2 presents a viable alternative for spinal anesthesia, potentially offering improved onset characteristics.
• Enhanced solubility may contribute to a safer drug profile by minimizing precipitation in the cerebrospinal fluid.
• Findings support further investigation into bupivacaine-CO2 for clinical applications in regional anesthesia.